Literature DB >> 17086530

Outcome of percutaneous coronary intervention in HIV-infected patients.

Amit Segev1, Warren J Cantor, Bradley H Strauss.   

Abstract

We report the long-term outcome of percutaneous coronary interventions (PCI) in 12 HIV-infected patients. Two patients died from a HIV-related infection and seven patients suffered from severe clinical and/or angiographic restenosis requiring additional interventions or causing severe angina pectoris. Only three patients remained symptom free. We conclude that HIV-infected patients should be considered as high risk group and treated routinely with drug-eluting stents.

Entities:  

Mesh:

Year:  2006        PMID: 17086530     DOI: 10.1002/ccd.20774

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  11 in total

Review 1.  Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy.

Authors:  Fabrizio D'Ascenzo; Enrico Cerrato; Giuseppe Biondi-Zoccai; Claudio Moretti; Pierluigi Omedè; Filippo Sciuto; Mario Bollati; Maria Grazia Modena; Fiorenzo Gaita; Imad Sheiban
Journal:  Eur Heart J       Date:  2011-12-20       Impact factor: 29.983

2.  Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease.

Authors:  Eliseo A Eugenin; Susan Morgello; Mary E Klotman; Arevik Mosoian; Patrick A Lento; Joan W Berman; Alison D Schecter
Journal:  Am J Pathol       Date:  2008-02-29       Impact factor: 4.307

3.  Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions.

Authors:  Gibson B Kagaruki; Mary T Mayige; Ester S Ngadaya; Godfather D Kimaro; Akili K Kalinga; Andrew M Kilale; Amos M Kahwa; Godlisten S Materu; Sayoki G Mfinanga
Journal:  BMC Public Health       Date:  2014-09-02       Impact factor: 3.295

4.  Unusual Response of Subclavian In-Stent Restenosis to Balloon Angioplasty in a Patient with HIV.

Authors:  Mohammad Atif Rana; Jagan Beedupalli; Nuri I Akkus
Journal:  Case Rep Vasc Med       Date:  2015-01-18

Review 5.  Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.

Authors:  Luis M Beltrán; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Jesús Egido; Juan García-Puig; Juan Antonio Moreno
Journal:  Vasc Health Risk Manag       Date:  2015-01-06

6.  Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection.

Authors:  Mohammad Alkhalil; Christopher P Conlon; Houman Ashrafian; Robin P Choudhury
Journal:  World J Clin Cases       Date:  2017-02-16       Impact factor: 1.337

7.  Knowledge and perception on type2 diabetes and hypertension among HIV clients utilizing care and treatment services: a cross sectional study from Mbeya and Dar es Salaam regions in Tanzania.

Authors:  Gibson B Kagaruki; Mary T Mayige; Esther S Ngadaya; Andrew M Kilale; Amos Kahwa; Amani F Shao; Godfather D Kimaro; Chacha M Manga; Doris Mbata; Godlisten S Materu; Ray M Masumo; Sayoki G Mfinanga
Journal:  BMC Public Health       Date:  2018-07-28       Impact factor: 3.295

8.  Aggressive In-Stent Restenosis after Carotid Artery Stenting in a Patient with HIV Infection.

Authors:  Dae Yeon Kim; Bum Sik Chin; Jang Hyun Baek; Jong Yun Lee; Jusun Moon
Journal:  J Clin Neurol       Date:  2021-01       Impact factor: 3.077

9.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08

Review 10.  What happens to cardiovascular system behind the undetectable level of HIV viremia?

Authors:  Gabriella d'Ettorre; Giancarlo Ceccarelli; Paolo Pavone; Pietro Vittozzi; Gabriella De Girolamo; Ivan Schietroma; Sara Serafino; Noemi Giustini; Vincenzo Vullo
Journal:  AIDS Res Ther       Date:  2016-04-27       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.